<DOC>
	<DOCNO>NCT02546635</DOCNO>
	<brief_summary>Part A : Food effect ( single oral dose 500 mg AX-024.HCl fast fed state ) Eight ( 8 ) healthy male volunteer receive single dose 500 mg AX-024.HCl fast state ( 10 h overnight fast ) , return 2 week later receive dose AX-024.HCl follow meal . Part B : Multiple dos ( daily dose AX-024.HCl Placebo 10 day ) . Part B double-blind , dose escalating , placebo control , randomise , multiple dose study assess tolerability , safety pharmacokinetics 24 healthy male subject . Subjects allocate one 2 dosing cohort . Each cohort 12 subject 9 subject randomise receive AX-024.HCl 3 subject randomise receive placebo . There data review follow dose level . Dose administration subsequent cohort proceed satisfactory data review blind safety data plasma PK data previous cohort .</brief_summary>
	<brief_title>Potential Food Effect And Repeated Dosing AX-024.HCl In Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Subjects body mass index ( BMI ) 18 35 kg/m2 , inclusive . BMI = Body weight ( kg ) / [ Height ( ) ] 2 . Subjects must vegetarians consume abnormal diet . Subject clinically significant abnormal serum biochemistry , haematology coagulation ( Part B ) urine examination value within 21 day first dose . Subject negative urinary drug abuse screen , determine within 21 day first dose ( N.B . positive alcohol result may repeat discretion Investigator ) . Subject negative human immunodeficiency virus ( HIV ) hepatitis B surface antigen ( Hep B ) hepatitis C virus antibody ( Hep C ) result . Subject clinically significant abnormality 12lead electrocardiogram ( ECG ) determine within 21 day first dose . Subject history autoimmune disease , cardiac disease , kidney disease food intolerance . Male subject willing use 2 effective method contraception i.e . establish method contraception + condom , applicable ( unless anatomically sterile abstain sexual intercourse line prefer usual lifestyle subject ) Day 1 3 month afterwards . Subjects must available complete study ( include followup visit ) . Subjects must satisfy medical examiner fitness participate study Subjects must provide write informed consent participate study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>